PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Cady, Roger K.
TI  - AVP-825 Produces Effective, Well-Tolerated Migraine Relief
DP  - 2015 Jun 20
TA  - MD Conference Express
PG  - 8--9
VI  - 15
IP  - 9
4099  - http://mdc.sagepub.com/content/15/9/8.short
4100  - http://mdc.sagepub.com/content/15/9/8.full
AB  - AVP-825 is a product containing a low-dose powder form of sumatriptan that can be delivered intranasally to treat migraines. It is better tolerated than higher doses of oral sumatriptan and has a faster onset of action. A pooled analysis of 2 studies confirmed that AVP-825 confers rapid headache relief sustained over 48 hours.